How to Buy Allogene Therapeutics Stock [2024]

Summary: Allogene Therapeutics, a clinical-stage biotech company, is publicly listed on the NASDAQ Exchange with the ticker ALLO. You can buy Allogene Therapeutics stock with online trading platforms like eToro.

Highly Rated Stock Trading & Investing Platform

Invest in 2,800+ stocks and other assets including 70+ cryptocurrencies and commodities.
0% commission on buying stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.

30+ million Users

Get Started

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

About Allogene Therapeutics

Allogene Therapeutics’ homepage. Source: Alloigone.com

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a California-based clinical-stage immuno-oncology company that develops genetically engineered allogeneic T cell therapies for cancer treatment.

Established in 2017, the company’s trailblazing endeavors include the development, manufacturing, and commercialization of breakthrough therapies such as:

UCART19: An allogeneic chimeric antigen receptor (CAR) T cell candidate designed to combat both pediatric and adult R/R CD19 positive B-cell ALL;
ALLO-501 & ALLO-501A: Anti-CD19 allogeneic CAR T cell candidates undergoing Phase I and Phase I/II clinical trials, respectively. While ALLO-501 targets R/R non-Hodgkin lymphoma, ALLO-501A is being explored for its potential in treating R/R large B-cell lymphoma or transformed follicular lymphoma;
ALLO-715: In its Phase I clinical trial, this allogeneic CAR T cell candidate is set to treat R/R multiple myeloma;
ALLO-605: Another promising candidate being explored for the treatment of multiple myeloma;
ALLO-647: An anti-CD52 monoclonal antibody;
CD70: Under investigation to treat renal cell cancer.
ALLO-316: An allogeneic CAR T cell candidate developed to treat immune checkpoint inhibitors;
DLL3: Aimed at treating small cell lung cancer and aggressive neuroendocrine tumors;
Claudin 18.2: Targeting gastric and pancreatic cancers.

Allogene Therapeutics is listed on the Nasdaq Exchange under the ticker ALLO.

How to buy Allogene Therapeutics stock? Step-by-step process

Follow these four steps to buy Allogene Therapeutics stock:

Select an online broker;
Set up and fund your account;
Purchase ALLO shares;
Periodically monitor and adjust your investment as necessary.

Step 1: Choose a broker

To buy Allogene Therapeutics stock, begin by selecting a dependable online broker.

From our assessment, eToro stands out as the best choice for investing in ALLO and will offer you the following:

Commission-free stock trading;
2,000+ stocks from 17 exchanges;
Fractional shares available;
User-friendly platform.

Highly Rated Stock Trading & Investing Platform

Invest in 2,800+ stocks and other assets including 70+ cryptocurrencies and commodities.
0% commission on buying stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.

30+ million Users

Get Started

For those looking to avoid the inherent volatility of biotech penny stocks, consider these established biotech companies instead:

Pfizer (NYSE: PFE);
Moderna (NASDAQ: MRNA);
Sanofi (NASDAQ: SNY);
Eli Lilly (NYSE: LLY);
Biogen (NASDAQ: BIIB);
Amgen (NASDAQ: AMGN);
Gilead Sciences (NASDAQ: GILD);
Bayer (FWB: BAYN);
Thermo Fisher Scientific (NYSE: TMO).

How to find the best online broker?

Consider the following aspects when selecting a broker:

Regulation: Ensure the broker is regulated by a recognized financial authority;
Fee structure: Understand all associated fees, including commission, spreads, and any hidden costs;
Trading platform: Check the usability, features, and reliability of their platform;
Product offerings: Confirm they provide access to the assets or markets you’re interested in;
Fractional shares: Determine if the broker offers fractional share trading, which allows you to invest by the dollar amount;
Account types: Evaluate the types of accounts they offer, such as margin or retirement accounts;
Security: Ensure robust security measures to protect your assets and data;
Research and education: Look for valuable research tools, educational resources, and market analysis.

Step 2: Open and fund your account

After choosing your broker, sign up on their platform. Once your account has been approved, you can fund it using your preferred method, e.g., a bank transfer, credit card, or a third-party payment system like PayPal.

Step 3: Place your order and invest in ALLO

To buy Allogene Therapeutics stock:

Search for Allogene Therapeutics by its ticker symbol ALLO;
Choose your order type, either a market order for immediate purchase or a limit order at a specified price;
Set your investment amount in dollars or the number of shares;
Review all details carefully before finalizing the transaction.

Step 4: Monitor your investment

To monitor your investment in Allogene Therapeutics:

Set up alerts for Allogene Therapeutics news and stock price changes;
Regularly review the company’s financial statements and announcements;
Track broader trends in the biotechnology sector;
Use your broker’s analytical tools for insights;
Periodically re-evaluate the stock’s performance against your investment goals.

Allogene Therapeutics stock price today

Pros and cons of investing in Allogene Therapeutics

Pros

Diverse product pipeline: The company has several product candidates at different stages of development, diversifying potential future revenue streams;
Collaborations and partnerships: Allogene has collaborations with major industry players like Pfizer, Servier, and Cellectis, which can facilitate resources, knowledge, and potential market reach;
Addressing high-need areas: The company is working on therapies for hard-to-treat cancers, which, if successful, can address significant unmet medical needs.

Cons

Clinical stage risks: As a clinical-stage company, there’s always the risk that its products may not successfully complete clinical trials or gain regulatory approval;
Financial uncertainty: Like many biotech firms, Allogene might operate at a loss until one or more of its therapies gets commercialized;
Regulatory challenges: Gaining FDA approval for treatments, especially innovative ones, is a long, expensive, and uncertain process;
Competition: The oncology and immuno-oncology sectors are highly competitive, with many companies working on similar treatments;
Penny stock volatility: Allogene Therapeutics may exhibit higher price volatility and offer lower liquidity as a penny stock. This can lead to greater price swings, making the investment more unpredictable and potentially increasing the risk of loss for investors.

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

FAQs about how to buy Allogene Therapeutics stock